U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...

A genetic disorder, Huntington’s leads to the breakdown of nerves and a progressive inability to think, move and function. No treatment has so far been approved to slow the condition’s march, although ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC ...